{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-265852","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-06-10T20:15:16+00:00","discovered_at":"2026-06-10T20:17:00.345159+00:00","generated_at":"2026-06-10T20:21:48.548911+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Syndax shareholders approve 2026 equity plans; 7.2M new shares reserved","bullets":["Stockholders approved 2026 Equity Incentive Plan authorizing 7,200,000 new shares plus returning shares from prior plan.","Stockholders also approved 2026 Employee Stock Purchase Plan as successor to 2015 ESPP; no rollover of prior shares.","Proposal 4 (2026 Plan) passed with 33,333,263 for vs. 25,392,051 against; Proposal 5 (ESPP) passed with 58,661,941 for.","All director nominees elected and advisory vote on executive compensation passed; ratification of auditor approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-265852","json":"https://secwatch.observer/filing/0001193125-26-265852.json","markdown":"https://secwatch.observer/filing/0001193125-26-265852.md","text":"https://secwatch.observer/filing/0001193125-26-265852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/0001193125-26-265852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/sndx-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:21:48.548911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"098ca417fd46cb05ab4472a460721fe01b5ca8be","claim":"Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2026-06-10 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 55,688,039 2,985,350 89,474 8,034,588","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/0001193125-26-265852-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"8ff1dc7e6dee8296a7b361c7c0af3f6cf698d61a","claim":"Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2026-06-10 meeting.","evidence_excerpt":"Pierre Legault 37,294,888 21,467,975 8,034,588 Michael A. Metzger 58,113,110 649,753 8,034,588","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/0001193125-26-265852-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"c09ba5a5996d58a0b7fc544cd7a055354ef36dc1","claim":"Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2026-06-10 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 66,603,912 162,947 30,592 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/0001193125-26-265852-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"c8f68bb6ccfc92f4c65666cd84ecb4d5cac57de3","claim":"Syndax Pharmaceuticals Inc shareholders approved Approval of the 2026 Plan at the 2026-06-10 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 33,333,263 25,392,051 37,549 8,034,588","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/0001193125-26-265852-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"da3bcf0e9b82a2362d8f6fd9547120f22a65c7e7","claim":"Syndax Pharmaceuticals Inc shareholders approved Approval of the 2026 ESPP at the 2026-06-10 meeting.","evidence_excerpt":"For Against Abstain Broker Non-Votes 58,661,941 74,047 26,875 8,034,588","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/0001193125-26-265852-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}